Objective： Angiogenic therapy is emerging as a potential strategy for the treatment of ischemic heart disease but is limited by a relatively short half-life of growth factors. Fibrin glue （FG） provides a reservoir ...Objective： Angiogenic therapy is emerging as a potential strategy for the treatment of ischemic heart disease but is limited by a relatively short half-life of growth factors. Fibrin glue （FG） provides a reservoir for controlledrelease of growth factors. The aim of this study was to evaluate the effects of basic flbroblast growth factor （bFGF） incorporating FG on angiogenesis and cardiac performance in a canine infarct model. Methods： Acute myocardial infarction was induced by ligation of the left anterior descending coronary artery （LAD）. Group Ⅰ （n=6） underwent ligation of LAD alone. In Group Ⅱ, transmural channels were created in the infarct area （n=6）. In Group Ⅲ, nontransmural channels were created to locate FG cylinders containing bFGF （n=6）. Eight weeks after operation, myocardial perfusion was assessed by single photon emission computed tomography, cardiac function by echocardi- ography, and vascular development by immunohistochemical staining. Results： Total vascular density and the number of large vessels （internal diameter ≥50 pro） were dramatically higher in Group Ⅲ than in Groups Ⅰ and Ⅱ at eight weeks. Only the controlled-release group exhibited an improvement in regional myocardial perfusion associated with lower defect score. Animals in Group Ⅲ presented improved cardiac regional systolic and diastolic functions as well as global systolic function in comparison with the other two groups. Conclusions： Enhanced and sustained angiogenic response can be achieved by controlled-release bFGF incorporating FG within transmyocardial laser channels, thus enabling improvement in myocardial perfusion and cardiac function.展开更多
基金Project supported by the National Natural Science Foundation of China (No. 81070166)the Scientific Research Common Program of Beijing Municipal Commission of Education (No. KM201010 025020),China
文摘Objective： Angiogenic therapy is emerging as a potential strategy for the treatment of ischemic heart disease but is limited by a relatively short half-life of growth factors. Fibrin glue （FG） provides a reservoir for controlledrelease of growth factors. The aim of this study was to evaluate the effects of basic flbroblast growth factor （bFGF） incorporating FG on angiogenesis and cardiac performance in a canine infarct model. Methods： Acute myocardial infarction was induced by ligation of the left anterior descending coronary artery （LAD）. Group Ⅰ （n=6） underwent ligation of LAD alone. In Group Ⅱ, transmural channels were created in the infarct area （n=6）. In Group Ⅲ, nontransmural channels were created to locate FG cylinders containing bFGF （n=6）. Eight weeks after operation, myocardial perfusion was assessed by single photon emission computed tomography, cardiac function by echocardi- ography, and vascular development by immunohistochemical staining. Results： Total vascular density and the number of large vessels （internal diameter ≥50 pro） were dramatically higher in Group Ⅲ than in Groups Ⅰ and Ⅱ at eight weeks. Only the controlled-release group exhibited an improvement in regional myocardial perfusion associated with lower defect score. Animals in Group Ⅲ presented improved cardiac regional systolic and diastolic functions as well as global systolic function in comparison with the other two groups. Conclusions： Enhanced and sustained angiogenic response can be achieved by controlled-release bFGF incorporating FG within transmyocardial laser channels, thus enabling improvement in myocardial perfusion and cardiac function.
